GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Accumulated Depreciation

GMAB (Genmab AS) Accumulated Depreciation : $0 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Genmab AS's annual accumulated depreciation increased from Dec. 2021 ($-56 Mil) to Dec. 2022 ($-70 Mil) and increased from Dec. 2022 ($-70 Mil) to Dec. 2023 ($-99 Mil).

Genmab AS Accumulated Depreciation Historical Data

The historical data trend for Genmab AS's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Accumulated Depreciation Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.11 -43.17 -55.92 -70.48 -98.91

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -98.91 - - -

Genmab AS Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Genmab AS Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Genmab AS's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Accumulated Depreciation
Comparable Companies
OCSE:ZEAL OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE UTHR MRNA NEUP SMMT INCY
Traded in Other Exchanges
GNMSF:USA GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Website
https://www.genmab.com
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.